The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
about
Altered radiation fractionation schedules for clinically localised and locally advanced prostate cancerBig Data Analytics for Prostate RadiotherapyEffects of Charged Particles on Human Tumor CellsLow temperature plasma: a novel focal therapy for localized prostate cancer?Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.Impact of treatment planning and delivery factors on gastrointestinal toxicity: an analysis of data from the RADAR prostate radiotherapy trial.MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer.Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeksPatient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer.Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy.Stereotactic radiotherapy of the prostate: fractionation and utilization in the United States.Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer.Hypofractionated helical intensity-modulated radiotherapy of the prostate bed after prostatectomy with or without the pelvic lymph nodes - the PRIAMOS trialStereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early resultsProctitis following stereotactic body radiation therapy for prostate cancerLow incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancerA single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.Radical prostatectomy and intraoperative radiation therapy in high-risk prostate cancer.Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging.21 years of biologically effective doseGastrointestinal radiation injury: symptoms, risk factors and mechanismsDosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumesPhase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancerStereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or without image guided radiotherapy.Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.Reducing biochemical recurrence rates in EBRT-treated prostate cancer patients: the influence of dose and dose per fraction.Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study.Novel treatment methods for localized prostate cancer: hypofractionated robotic radiation therapy and adjuvant chemotherapy.Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.Normal Tissue Complication Probability (NTCP) modeling of late rectal bleeding following external beam radiotherapy for prostate cancer: A Test of the QUANTEC-recommended NTCP modelHistopathologic effects of hypofractionated robotic radiation therapy on malignant and benign prostate tissue.Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer.What do we know about the α/β for prostate cancer?Single institution's dosimetry and IGRT analysis of prostate SBRT.Potency preservation following stereotactic body radiation therapy for prostate cancer.Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer.
P2860
Q24186971-536B68D0-0239-44AB-A6B5-8A121294D096Q26744485-A2EB7C4B-847D-4A10-AD4A-5B08CF211272Q26767252-F6100A90-9719-4A27-89D4-DA1F9458E45AQ27027563-5E767BD7-DB75-44E2-B534-C37494A79866Q30489515-589AA0D1-6379-4CA0-B57B-58E8E3A02F61Q30877686-7EEA36ED-1845-460A-A149-5E377ECB23E3Q30988899-20939F1F-3948-455E-BE2F-5A5ADD119DFBQ33613649-6B85917B-D2DD-4143-9678-7A0010DD5252Q33851417-358B872E-BC26-424C-AD86-F0D44679BAACQ33860897-D1739067-9AB9-418B-AA37-925802C04C27Q33887571-52B57DA6-9492-4225-AA35-150C04B680DAQ33919686-50D4F7EE-5449-4702-A793-FC4D667563F8Q33985573-53710221-8DA2-4460-92E3-0C7B5D45C008Q34462816-1D20F2C4-8793-427A-AB17-FCC694DBAF65Q34660610-2503E184-E1D3-4F95-9785-C3C460BB45BDQ34748877-EB1F8DA8-9758-4747-8327-4E35211E8F1EQ34871906-76E37708-4D66-4D0E-A387-30EAD11FF58BQ35019637-182697D4-2915-4602-9867-A93C5585C93BQ35174871-93E1FF10-5121-45B8-B123-D2DC06E91310Q35779513-50891B26-463E-4042-979A-21E4D125193FQ36015152-853A6E6C-AA9F-48CB-93E5-79889D37FA0FQ36324701-EF1E30D2-A573-4003-B9C6-9838AB5D8332Q36541173-ABFAACE6-0EB7-4B3B-B6DE-781A869C4483Q36575937-3A055823-F627-4CBD-A738-FC738B150A75Q36625206-4127E33E-D9C5-4A9B-9AB5-2A94EAB8E597Q36722591-B4E80FDA-B788-4503-95A0-8A45DA75D119Q36953209-BAED22DA-5B2D-4A1D-B668-C338C4C60227Q36982057-16C28D92-A0CD-465E-B54C-DCE48DB341F5Q37016012-CC4ED3EE-28E5-41D9-AC0F-D4A42D401587Q37116581-43ACA2ED-21D9-4FBE-881A-AA3839C7EAA6Q37512971-0B9C7D3B-E700-4004-B84C-808D524AAFA1Q37546045-462AF0BB-BDFB-4183-AB27-D7CE600053B8Q37627132-7BF47CA2-FF82-4570-B25A-1AD656AEDFA4Q37787278-98CDC570-DD0D-4511-A618-8FF71097B617Q37808695-F469842A-DFFA-436A-9FB1-03B36C5FE36FQ37823204-F647A553-2BAD-4577-A37E-D8006635FBD6Q38023478-AA771AB3-C800-4026-9B02-06A23F76ABD4Q38137328-45D0EF93-0F84-4506-A940-88B54289E8CEQ38158080-4C9BBE6C-BC5C-4FB0-BF32-2E9BD01CBB01Q38172209-315AF1B9-4F48-4271-9009-984A9D489603
P2860
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
@ast
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
@en
type
label
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
@ast
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
@en
prefLabel
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
@ast
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
@en
P2860
P1433
P1476
The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
@en
P2093
Jack F Fowler
P2860
P304
P356
10.1080/02841860410002824
P577
2005-01-01T00:00:00Z